Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma 2Immunoblastic Lymphadenopathy 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, T-Cell 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3romidepsin 2pembrolizumab 2etoposide phosphate 2duvelisib 2Melphalan 2Brentuximab Vedotin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1prednylidene 1glofitamab 1fludarabine phosphate 1fludarabine 1deltacortene 1cemiplimab 1brincidofovir 1belinostat 1X-Rays 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × romidepsin × 1 year × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡